Skip to main content
OpenTrials
Recruiting

NCT Number: NCT03327961

Scaffold in Emilia Romagna and in the MAGIC Network

The prospective study will investigate the clinical performance and long-term safety of scaffold implantation in a real world regional setting. The protocol includes two different networks. The first network includes all cath-labs in the Emilia-Romagna region (SHERPA). The second includes the centers partecipating into the MAGIC retrospective study. Both networks joined into the prospective SHERPA-MAGIC project. Investigators from both networks agreed in indications and strategy implanatation described by the protocol. In each center, after IRB approval, the patients will be enrolled according to established criteria.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

AO San Giovanni di Dio, Agrigento, Italy

Loading trial locations.

About this study

Coronary stents are the default devices for the treatment of coronary artery disease in percutaneous coronary intervention (PCI) according to existing guidelines. However, thrombosis and restenosis are still the main limitations of current permanent metallic stents. In contrast to Bare Metal Stents (BMSs), Drug Eluting Stents (DESs) have a reduced restenosis rate due to the presence of antiproliferative agents in the coating layer of the stent surface and reduced rate of repeat revascularisation. However, late and very late stent thrombosis remains the limitation of DES in spite of prolonged dual antiplatelet therapy. Bioabsorbable scaffolds have been introduced to overcome limitations of permanent metallic stents.

The aim of this observational prospective study is to investigate the clinical performance and long-term safety of scaffold in a real world regional setting.

The investigators agreed in the following preferential/optimal indications:

  • complete revascularization in patients with age <65 years
  • revascularization of long lesions (>24 mm), especially located in left anterior descending
  • spontaneous coronary dissection

The investigators agreed in the following strategy implantation:

  • mandatory predilatation
  • sizing 1:1
  • to avoid vessel with reference vessel diameter <2.8 mm and >3.8 mm
  • to avoid vessel with severe calcifications
  • mandatory postdilation with non compliant balloon ≥0.5 the scaffold diameter

The study organization is based on:

DATA SAFETY MONITORING BOARD (DSMB) All adverse events will be reported to the DSMB and reviewed on an on-going basis throughout the subject enrolment and follow-up period to ensure the safety of subjects enrolled in this study. The DSMB may request additional information as needed.

CORE LABORATORY ANALYSIS All coronary artery angiographies and percutaneous coronary interventions will be reviewed by an indipendent core-lab. The core-lab will perform quantitative coronary analysis and assessment of the agreement between implantation technique in each case and established criteria

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • subjects >18 years
  • sign of the patients informed consent
  • implanation of at least one scaffold

Exclusion criteria

  • inability to garantuee at least one year follow-up
  • inabiliuty to garantuee at least one year compliance to dual antiplatelet regimen

Treatment and study plan

scaffold

Device

implantation of scaffold (eg Magmaris, Desolve, Others)

Primary outcomes

  1. Device Oriented Cardiac Events

    Time frame: 1 year

    cumulative occurence of cardiovascular death, target vessel myocardial infarction and target vessel revascularization. Target is defined the vessel treated with scaffold

Study contacts

Contact information is provided by the study sponsor or research team.

Elisa Mosele

CONTACT

[email protected]

0532236450 ext. +39

Veronica Lodolini

CONTACT

[email protected]

0532236450 ext. +39

Sponsors and collaborators

Lead sponsor

University Hospital of Ferrara

Other

Registry information

Official study title

Scaffold Implantation in Emilia-Romagna Plus Multi Absorbable Gears Intra Coronary

Acronym: SHERPA-MAGIC

Important dates

Study start
2017
Primary completion
2029
Study completion
2034
First posted
Nov 1, 2017
Registry last updated
May 1, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.